In more recent clinical trials they have even been shown to reduce the risk of adverse outcomes in chronic kidney disease and the risk of major adverse cardiovascular events
Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes
Technically yes, but practically it creates a contradiction
With updated clinical guideline recommendations and changes to drug labeling in 20202022, as well as the 2021 approval of finerenonethe only new drug indicated for CKD associated with type 2 diabetes approved in this time periodit is of interest to understand how patterns of SGLT2i and GLP-1 RA use and characteristics of patients prescribed these medications in the US may have changed
If youre on a GLP-1 medication Ozempic, Wegovy, Mounjaro and youve been told to add NAD+ to your protocol, youve probably encountered some version of the same pitch: NAD+ gives you the energy back that GLP-1 drugs take away
Why titration stretches the timeline Semaglutide protocols are typically introduced gradually rather than at a full level from day one
.png)
